Kim N.
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Cancer Research top 0.05%
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
Papers in
-
- Prostate Cancer Treatment and Research 271
- Prostate Cancer Diagnosis and Treatment 25
- Oncology 132
- Cancer Treatment and Pharmacology 32
- PARP inhibition in cancer therapy 32
- Cancer Immunotherapy and Biomarkers 21
- Co-authors
- Karim Fizazi (59 shared papers)Ronald de Wit (5 shared papers)Johann S. de Bono (52 shared papers)Fred Saad (55 shared papers)Ian F. Tannock (6 shared papers)Mario A. Eisenberger (4 shared papers)Mark Rosenthal (4 shared papers)Stéphane Oudard (6 shared papers)
- Journals
- Journal of Clinical Oncology (180 papers)Clinical Cancer Research (15 papers)European Urology (14 papers)The Journal of Urology (13 papers)The Lancet Oncology (10 papers)
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Kim N.
353 papers receiving 26.7k citations
Kim N.'s Hit Papers
Peers
Comparison fields: 5 of 142
- Pulmonary and Respiratory Medicine 18.6k
- Cancer Research 5.8k
- Oncology 6.3k
- Radiology, Nuclear Medicine and Imaging 3.7k
- Endocrinology, Diabetes and Metabolism 1.6k
Countries citing papers authored by Kim N.
This map shows the geographic impact of Kim N.'s research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim N. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim N. more than expected).
Fields of papers citing papers by Kim N.
This network shows the impact of papers produced by Kim N.. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim N.. The network helps show where Kim N. may publish in the future.
Co-authors
The 25 scholars most cited alongside Kim N., linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 373 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer Hit paper breakdown → | 2004 | 4478 |
| 2 | Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy Hit paper breakdown → | 2012 | 3428 |
| 3 | Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2021 | 1605 |
| 4 | Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study Hit paper breakdown → | 2009 | 1567 |
| 5 | Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer Hit paper breakdown → | 2017 | 1478 |
| 6 | Olaparib for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2020 | 1473 |
| 7 | Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Hit paper breakdown → | 2012 | 1069 |
| 8 | Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer Hit paper breakdown → | 2019 | 943 |
| 9 | Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2019 | 549 |
| 10 | Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2020 | 496 |
| 11 | Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer Hit paper breakdown → | 2015 | 380 |
| 12 | Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer Hit paper breakdown → | 2018 | 356 |
| 13 | Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study Hit paper breakdown → | 2021 | 309 |
| 14 | 2017 | 293 | |
| 15 | Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer Hit paper breakdown → | 2016 | 274 |
| 16 | 2007 | 252 | |
| 17 | 2005 | 226 | |
| 18 | Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial Hit paper breakdown → | 2019 | 225 |
| 19 | 2014 | 217 | |
| 20 | 2012 | 205 |
About Kim N.
Kim N. is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, Cancer Research and Molecular Biology, having authored 373 papers that have together received 27.1k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (271 papers), Radiopharmaceutical Chemistry and Applications (94 papers), Cancer Genomics and Diagnostics (56 papers), Cancer, Lipids, and Metabolism (33 papers), Cancer Treatment and Pharmacology (32 papers), PARP inhibition in cancer therapy (32 papers), Prostate Cancer Diagnosis and Treatment (25 papers) and Cancer Immunotherapy and Biomarkers (21 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (18.6k citations), Cancer Research (5.8k citations), Oncology (6.3k citations), Radiology, Nuclear Medicine and Imaging (3.7k citations) and Endocrinology, Diabetes and Metabolism (1.6k citations). Kim N. has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Karim Fizazi, Ronald de Wit, Johann S. de Bono, Fred Saad, Ian F. Tannock, Mario A. Eisenberger, Mark Rosenthal, Stéphane Oudard, Nicholas D. James and Christine Théodore. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, European Urology, The Journal of Urology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.